REGENERON PHARMACEUTICALS, INC for REGENERON PHARMACEUTICALS, INC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022
| Lobbyist | Covered position, as disclosed |
|---|---|
| MAYA BERMINGHAM | — |
| MADDIE DAVIDSON New | Health Policy Director, Legislative Assistant, Sen. Mike Braun; Professional Staff Member, Staff Assistant, Senate Committee on Finance |
| EBEN DUROSS New | — |
| KATHERINE HADDAD | — |
| VALERIE VOLPE | — |
Medicare/Medicaid MMM
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers, including ancillary care
| Lobbyist | Covered position, as disclosed |
|---|---|
| MADDIE DAVIDSON New | Health Policy Director, Legislative Assistant, Sen. Mike Braun; Professional Staff Member, Staff Assistant, Senate Committee on Finance |
| EBEN DUROSS New | — |
| KATHERINE HADDAD | — |
| VALERIE VOLPE | — |
Copyright/Patent/Trademark CPT
Patent issues relating to biopharmaceutical manufacturers; intellectual property rights
| Lobbyist | Covered position, as disclosed |
|---|---|
| MAYA BERMINGHAM | — |
| MADDIE DAVIDSON New | Health Policy Director, Legislative Assistant, Sen. Mike Braun; Professional Staff Member, Staff Assistant, Senate Committee on Finance |
| EBEN DUROSS New | — |
| VALERIE VOLPE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.